Ocugen, Inc.

As of June 30, 2026, Ocugen Inc carries a market capitalization of 9.48B, placing it among publicly traded companies globally. Its enterprise value stands at 9.27B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Ocugen Inc's next confirmed earnings release is scheduled for November 10, 2026.

As of June 30, 2026, Ocugen Inc has 339.04M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 112.18, and the price-to-book ratio stands at -32.78.

These figures are as of June 30, 2026. The EV/Sales ratio of 115.87 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 9.27B versus a market cap of 9.48B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Ocugen Inc maintains a current ratio of 0.80, meaning it holds 0.8x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -531.44, indicating conservative leverage, while an interest coverage ratio of -7.96 demonstrates limited ability to service its debt obligations.

These figures cover the twelve months ended June 30, 2026. Return on assets (ROA) is negative at -92.03, reflecting losses generated across the asset base. The company generates approximately 722,527.57 in revenue per employee across its workforce of 110.75, a quick read on workforce productivity versus industry peers.

As of the close on October 20, 2026, Ocugen Inc's stock has declined approximately 49.14% over the past 52 weeks. The 50-day moving average sits at 21.50, while the 200-day moving average is 25.98.

Over the twelve months ended June 30, 2026, Ocugen Inc generated 80.02M in revenue and converted that into -1.43B in net income, yielding earnings per share of -4.45. EBITDA reached -1.17B, while operating income came in at -1.20B.

As of June 30, 2026, Ocugen Inc holds 1.75B in cash and equivalents against 1.54B in total debt, resulting in a net debt position of -278.55M. Total book value stands at -289.26M, with working capital of -460.53M providing operational flexibility.

Ocugen Inc produced -1.06B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -2.67M in capital expenditures, free cash flow totaled -1.07B - equivalent to -3.32 per share.

These figures cover the twelve months ended June 30, 2026. The operating margin of -1,504.43 and net profit margin of -1,786.27 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -11.88: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -24.66, meaning Ocugen Inc raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Ocugen Inc's most recent stock split took place on September 30, 2019 with a 60:1 split ratio.

As of June 30, 2026, Ocugen Inc has an Altman Z-Score of -4.83, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.